And what I think is happening here is Actavis is waiting on the first study or two results. They have this deal with Purdue and addressed in the article written recently. Actavis has to come up with twice daily abuse resistant to market or end up buying it from Purdue. Well where is actavis going to get it. Pretty darn obvious now.

And once approved, you BE study the once a day. Also watch this Europe deal too. I really need to listen again to that part.